You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

51 search results for: chronic inflammation

Type 2 <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Contribution of Type 2 Cytokines to <b>Inflammation</b> and Itch in AD, PN, and CSU

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

How Does Protective Type 2 Immunity Become Harmful Type 2 <b>Inflammation</b>?

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

20 min

Dermatology

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

2 min

Dermatology

Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.

expert video

Mast Cells and the Neuroimmune Axis in CSU

10 min

Dermatology

A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Defining Mechanisms of Anosmia in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens examines what is known and what else should be explored to understand the mechanisms of anosmia in patients with CRSwNP.

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

expert video

ERS-ISIAN 2023 | Optimizing Patient Outcomes in CRSwNP: Guidelines and Shared Decision-Making

29 min

Rhinology

Prof. Peter Hellings and Dr. Stella Lee discuss the current landscape of CRSwNP guidelines and treatment for optimizing patient outcomes.

expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

7 min

Rhinology

Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region